BOSTON (MarketWatch) -- Eli Lilly & Co. said Monday that it plans to buy cancer-drug developer ImClone Systems for $70 a share, or about $6.5 billion, in an all-cash deal that is not subject to ...

Despite the objections of his assistant, Martha Stewart’s stockbroker ordered the assistant to tell Stewart that the founder of ImClone Systems ... if the price slipped below $60 a share.

BOSTON (Reuters) - ImClone Systems Inc said on ... declined to comment. A $70 a share offer would represent a premium of 51 percent over ImClone's closing price of $46.44 on July 30, the day ...

Waksal, founder of biotech company ImClone Systems Inc., is due to be sentenced ... drove a run-up in ImClone’s stock price until late 2001, when the fortunes of Waksal and ImClone soured.

Shares of ImClone Systems ... Charts) fell nearly 8 percent after Jim Reddoch, analyst for Friedman, Billings, Ramsey, downgraded the stock to "market perform" and lowered his 12-month price ...

ImClone Systems (IMCL) has rejected an unsolicited ... representing a premium of over 10% from the closing price on Tuesday of $63.65 per share. While numerous big pharma companies could be ...

ImClone Systems’ share price surged by more than 18% on the Nasdaq Stock Exchange yesterday after clinical data showed that the firm’s oncology drug, Erbitux (cetuximab), used in combination with ...

Biotechnology company ImClone Systems Inc. said Wednesday that it ... a stake worth about $1 billion at the current share price. Under a contract running through 2018, if another company buys ...